XML 31 R16.htm IDEA: XBRL DOCUMENT v3.24.0.1

Accrued Expenses and Other Current Liabilities

12 Months Ended

Dec. 31, 2023

Schedule of Accrued Expenses and Other Current Liabilities [Abstract]

ACCRUED EXPENSES AND OTHER CURRENT LIABILITIES

8. ACCRUED EXPENSES AND OTHER CURRENT LIABILITIES 

Accrued expenses and other current liabilities consisted of the following as of the periods indicated:

		December 31,				December 31,
		2023				2022
Accrued research and development expense		$	1,799,583			$	1,600,221
Accrued compensation and employee benefits			1,184,505				568,865
Accrued royalties			274,028				272,352
Others			438,264				468,150
Total		$	3,696,380			$	2,909,587

X

- Definition

The entire disclosure for accounts payable and accrued liabilities at the end of the reporting period.

+ References

Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef
-Name Accounting Standards Codification
-Topic 210
-SubTopic 10
-Section S99
-Paragraph 1
-Subparagraph (SX 210.5-02.19(a),20,24)
-Publisher FASB
-URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1

+ Details

Name:	us-gaap_AccountsPayableAndAccruedLiabilitiesDisclosureTextBlock
Namespace Prefix:	us-gaap_
Data Type:	dtr-types:textBlockItemType
Balance Type:	na
Period Type:	duration

X

- References

No definition available.

+ Details

Name:	us-gaap_AccruedLiabilitiesAndOtherLiabilitiesAbstract
Namespace Prefix:	us-gaap_
Data Type:	xbrli:stringItemType
Balance Type:	na
Period Type:	duration